• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Surrozen Inc.

    5/15/25 7:36:13 AM ET
    $SRZN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SRZN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Surrozen, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    86889P208

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    86889P208


    1Names of Reporting Persons

    DRIEHAUS CAPITAL MANAGEMENT LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    204,934.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    204,934.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    204,934.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.25 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Surrozen, Inc.
    (b)Address of issuer's principal executive offices:

    171 Oyster Point Blvd, Suite 400, South San Francisco, California, 94080
    Item 2. 
    (a)Name of person filing:

    Driehaus Capital Management LLC
    (b)Address or principal business office or, if none, residence:

    25 East Erie Street Chicago, Illinois 60611
    (c)Citizenship:

    USA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    86889P208
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    204934
    (b)Percent of class:

    6.25  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    204934

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    204934

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The shares reported by Driehaus Capital Management LLC (DCM) are held by numerous clients on a fully discretionary basis in accounts managed by DCM. Securities held in these clients' accounts are included in this report to reflect that DCM may have voting power and has dispositive power. To the best of DCM's knowledge, none of the referenced clients have the right to receive dividends or direct proceeds from the sale of interests relating to more than 5% of the class.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    DRIEHAUS CAPITAL MANAGEMENT LLC
     
    Signature:Janet McWilliams
    Name/Title:Janet McWilliams/General Counsel
    Date:05/15/2025
    Get the next $SRZN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SRZN

    DatePrice TargetRatingAnalyst
    1/30/2025$32.00Buy
    H.C. Wainwright
    1/3/2025$45.00Neutral → Buy
    Guggenheim
    10/11/2021$11.00Buy
    B of A Securities
    9/15/2021$20.00Buy
    Guggenheim
    9/7/2021$19.00Buy
    Stifel
    More analyst ratings

    $SRZN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Bjerkholt Eric

      4 - Surrozen, Inc./DE (0001824893) (Issuer)

      5/15/25 5:29:26 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Chai Christopher Y

      4 - Surrozen, Inc./DE (0001824893) (Issuer)

      5/15/25 5:26:22 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Haak-Frendscho Mary

      4 - Surrozen, Inc./DE (0001824893) (Issuer)

      5/15/25 5:25:19 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRZN
    Leadership Updates

    Live Leadership Updates

    See more
    • Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt

      SOUTH SAN FRANCISCO, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced that Eric Bjerkholt has been appointed to the Board of Directors. Surrozen's Board of Directors now includes nine members with extensive experience across diverse disciplines in biotechnology and pharmaceutical development. Mr. Bjerkholt brings extensive business leadership experience across a broad range of roles and is currently CFO of Chinook Therapeutics. He most recently served as CFO of Aimmune Therapeutics, Inc. overseeing t

      4/5/23 8:30:00 AM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Surrozen Announces Appointment of Liz Nguyen as Vice President and Head of Human Resources

      SOUTH SAN FRANCISCO, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Surrozen Inc. (NASDAQ:SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today announced that Elizabeth "Liz" Nguyen has been appointed as Vice President and Head of Human Resources (HR). Ms. Nguyen brings over 20 years of experience in organizational design, talent recruitment, building a performance culture, planning and leadership development. "Liz is joining Surrozen at a time of tremendous growth as we advance our two lead programs into the clinic and continue our momentum and progress on our broad research pipeline," said Craig Parker, President and Chief

      9/23/21 8:30:00 AM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRZN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Surrozen with a new price target

      H.C. Wainwright initiated coverage of Surrozen with a rating of Buy and set a new price target of $32.00

      1/30/25 7:17:42 AM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Surrozen upgraded by Guggenheim with a new price target

      Guggenheim upgraded Surrozen from Neutral to Buy and set a new price target of $45.00

      1/3/25 7:50:23 AM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • B of A Securities initiated coverage on Surrozen with a new price target

      B of A Securities initiated coverage of Surrozen with a rating of Buy and set a new price target of $11.00

      10/11/21 7:02:26 AM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRZN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Surrozen Inc.

      SC 13G/A - Surrozen, Inc./DE (0001824893) (Subject)

      11/14/24 4:34:39 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Surrozen Inc.

      SC 13G/A - Surrozen, Inc./DE (0001824893) (Subject)

      11/13/24 5:42:02 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Surrozen Inc.

      SC 13G/A - Surrozen, Inc./DE (0001824893) (Subject)

      11/8/24 11:26:54 AM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRZN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Column Group Iii Gp, Lp bought $11,999,991 worth of shares (1,034,482 units at $11.60) (SEC Form 4)

      4 - Surrozen, Inc./DE (0001824893) (Issuer)

      3/28/25 8:57:08 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Column Group Iii Gp, Lp bought $2,999,994 worth of shares (193,548 units at $15.50) (SEC Form 4) (Amendment)

      4/A - Surrozen, Inc./DE (0001824893) (Issuer)

      4/17/24 4:14:56 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Kutzkey Tim bought $2,999,994 worth of shares (193,548 units at $15.50) (SEC Form 4) (Amendment)

      4/A - Surrozen, Inc./DE (0001824893) (Issuer)

      4/17/24 4:10:51 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRZN
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Surrozen Inc.

      SCHEDULE 13G/A - Surrozen, Inc./DE (0001824893) (Subject)

      5/15/25 4:55:17 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Surrozen Inc.

      SCHEDULE 13G/A - Surrozen, Inc./DE (0001824893) (Subject)

      5/15/25 4:42:41 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Surrozen Inc.

      SCHEDULE 13G/A - Surrozen, Inc./DE (0001824893) (Subject)

      5/15/25 4:30:10 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRZN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway

      Newly granted patent is part of the expanding intellectual property portfolio directed to: -generating novel and selective Wnt surrogate molecules with potentially broad therapeutic utility and -incorporating novel discoveries related to requirements for efficient and selective Wnt pathway signaling SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt Pathway for tissue repair and regeneration, today announced the issuance of U.S. Patent No. 12,297,278. Surrozen has six issued U.S. patents, 10 patents issued in other countries, 11 patent fami

      5/14/25 8:30:01 AM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

      SOUTH SAN FRANCISCO, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a biotechnology company pioneering targeted therapeutics that selectively modulate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today announced financial results for the first quarter ended March 31, 2025, and provided a business update. Business Highlights Surrozen has pivoted its focus to its ophthalmology pipeline, leveraging its Wnt biology expertise and antibody technologies to develop novel treatments for severe eye diseases, including age-related macular degeneration (AMD) and diabetic retinopathy. The Company discont

      5/9/25 4:05:08 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates

      SOUTH SAN FRANCISCO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, with a focus on severe eye diseases, today provided fourth quarter and full year 2024 financial results and business updates. Research and Development Pipeline Highlights The company prioritized its ophthalmology pipeline programs that have the potential to provide new or improved treatment options in multiple severe and disabling eye diseases. Surrozen will focus its Wnt biology expertise and Wnt signal modulation antibody technologies on its oph

      3/31/25 4:05:16 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SRZN
    Financials

    Live finance-specific insights

    See more
    • Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress

      Enrolled first patient in SZN-043 Ph 1a clinical trial in chronic liver disease with data expected by the end of 2023 Expect to begin SZN-043 Ph1b clinical trial in severe alcoholic hepatitis in 2024 with proof-of-concept data expected in the second half of 2024 Expect to reinitiate SZN-1326 Ph1a clinical trial in healthy volunteers by mid-2023 with data expected by the end of 2023 Anticipate potential proof-of-concept data for SZN-1326 in ulcerative colitis in the second half of 2024 Expect to nominate a fourth product candidate by the end of 2023 Corporate prioritization and restructuring result in cash runway into the second half of 2024 SOUTH SAN FRANCISCO, Calif., March 22, 2023

      3/22/23 4:01:00 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023

      SOUTH SAN FRANCISCO, Calif., March 20, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. ("Surrozen" or the "Company") (NASDAQ:SRZN), today announced that it will report fourth quarter and full year 2022 financial results and provide a corporate and pipeline progress report on Wednesday, March 22, 2023 after the close of the U.S. financial markets.   Company management will host a live audio webcast at 4:30 PM Eastern Time to discuss the corporate update and pipeline progress. Interested parties may join the audio webcast via the Investor website at www.surrozen.com. To ensure a timely connection, it is recommended that individuals register at least 15 minutes prior to the start of the webcast. Ab

      3/20/23 4:30:00 PM ET
      $SRZN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care